Jeffrey A Vernon1, Eugene Grudnikoff2, Andrew J Seidman2, Thomas W Frazier3, Mani Sandhya Vemulapalli4, Priyanki Pareek1, Terry E Goldberg5, John M Kane6, Christoph U Correll7. 1. New York Medical College, Valhalla, NY, USA. 2. The Zucker Hillside Hospital, Psychiatry, North Shore-Long Island Jewish Health System, Glen Oaks, NY, USA. 3. Center for Autism, Pediatric Institute, Cleveland Clinic, Cleveland, OH, USA. 4. Atlanta VA Medical Center, Decatur, GA, USA. 5. The Zucker Hillside Hospital, Psychiatry, North Shore-Long Island Jewish Health System, Glen Oaks, NY, USA; Hofstra North Shore LIJ School of Medicine, Hempstead, NY, USA; The Feinstein Institute for Medical Research, Manhasset, NY, USA. 6. The Zucker Hillside Hospital, Psychiatry, North Shore-Long Island Jewish Health System, Glen Oaks, NY, USA; Hofstra North Shore LIJ School of Medicine, Hempstead, NY, USA; The Feinstein Institute for Medical Research, Manhasset, NY, USA; Albert Einstein College of Medicine, Bronx, NY, USA. 7. The Zucker Hillside Hospital, Psychiatry, North Shore-Long Island Jewish Health System, Glen Oaks, NY, USA; Hofstra North Shore LIJ School of Medicine, Hempstead, NY, USA; The Feinstein Institute for Medical Research, Manhasset, NY, USA; Albert Einstein College of Medicine, Bronx, NY, USA. Electronic address: ccorrell@lij.edu.
Abstract
BACKGROUND: Cognitive impairment in schizophrenia is disabling, but current treatment options remain limited. OBJECTIVE: To meta-analyze the efficacy and safety of adjunctive antidepressants for cognitive impairment in schizophrenia. DATA SOURCES AND STUDY SELECTION: PubMed, MEDLINE, PsycINFO, and Cochrane Library databases were searched until 12/2013 for randomized controlled trials comparing antidepressant augmentation of antipsychotics with placebo regarding effects on cognitive functioning in schizophrenia. DATA EXTRACTION: Two authors independently extracted data. Standardized mean differences (SMDs) were calculated for continuous outcomes and risk ratios for categorical outcomes. SMDs of individual cognitive tests were pooled on a study level within domains (primary outcome) and across domains. When results were heterogeneous, random instead of fixed effects models were used. RESULTS: We meta-analyzed 11 studies (duration = 8.7 ± 3.7 weeks) including 568 patients (mean age = 39.5 ± 6.9 years, males = 67.2%, illness duration = 12.5 ± 8.0 years). Antidepressants included mirtazapine (4 studies; n = 126), citalopram (2 studies; n = 231), fluvoxamine (1 study; n = 47), duloxetine (1 study; n = 40), mianserin (1 study; n = 30), bupropion (1 study; n = 61), and reboxetine (1 study; n = 33). Statistically significant, but clinically negligible, advantages were found for pooled antidepressants compared to placebo in executive function (Hedges' g = 0.17, p = 0.02) and a composite cognition score (Hedges' g = 0.095, p = 0.012). Depression improved with serotonergic antidepressants (p = 0.0009) and selective serotonin reuptake inhibitors (p = 0.009), but not with pooled antidepressants (p = 0.39). Sedation was more common with pooled antidepressants (p = 0.04). CONCLUSION: Adjunctive antidepressants do not demonstrate clinically significant effects on cognition in schizophrenia patients, however, larger studies, preferably in euthymic schizophrenia patients and using full neurocognitive batteries, are needed to confirm this finding.
BACKGROUND:Cognitive impairment in schizophrenia is disabling, but current treatment options remain limited. OBJECTIVE: To meta-analyze the efficacy and safety of adjunctive antidepressants for cognitive impairment in schizophrenia. DATA SOURCES AND STUDY SELECTION: PubMed, MEDLINE, PsycINFO, and Cochrane Library databases were searched until 12/2013 for randomized controlled trials comparing antidepressant augmentation of antipsychotics with placebo regarding effects on cognitive functioning in schizophrenia. DATA EXTRACTION: Two authors independently extracted data. Standardized mean differences (SMDs) were calculated for continuous outcomes and risk ratios for categorical outcomes. SMDs of individual cognitive tests were pooled on a study level within domains (primary outcome) and across domains. When results were heterogeneous, random instead of fixed effects models were used. RESULTS: We meta-analyzed 11 studies (duration = 8.7 ± 3.7 weeks) including 568 patients (mean age = 39.5 ± 6.9 years, males = 67.2%, illness duration = 12.5 ± 8.0 years). Antidepressants included mirtazapine (4 studies; n = 126), citalopram (2 studies; n = 231), fluvoxamine (1 study; n = 47), duloxetine (1 study; n = 40), mianserin (1 study; n = 30), bupropion (1 study; n = 61), and reboxetine (1 study; n = 33). Statistically significant, but clinically negligible, advantages were found for pooled antidepressants compared to placebo in executive function (Hedges' g = 0.17, p = 0.02) and a composite cognition score (Hedges' g = 0.095, p = 0.012). Depression improved with serotonergic antidepressants (p = 0.0009) and selective serotonin reuptake inhibitors (p = 0.009), but not with pooled antidepressants (p = 0.39). Sedation was more common with pooled antidepressants (p = 0.04). CONCLUSION: Adjunctive antidepressants do not demonstrate clinically significant effects on cognition in schizophreniapatients, however, larger studies, preferably in euthymic schizophreniapatients and using full neurocognitive batteries, are needed to confirm this finding.
Authors: Terry E Goldberg; Robert S Goldman; Katherine E Burdick; Anil K Malhotra; Todd Lencz; Raman C Patel; Margaret G Woerner; Nina R Schooler; John M Kane; Delbert G Robinson Journal: Arch Gen Psychiatry Date: 2007-10
Authors: Ruth S Barr; Melissa A Culhane; Lindsay E Jubelt; Rana S Mufti; Michael A Dyer; Anthony P Weiss; Thilo Deckersbach; John F Kelly; Oliver Freudenreich; Donald C Goff; A Eden Evins Journal: Neuropsychopharmacology Date: 2007-04-18 Impact factor: 7.853
Authors: Maria Rosaria Anna Muscatello; Rocco A Zoccali; Gianluca Pandolfo; Paolo Mangano; Simona Lorusso; Clemente Cedro; Fortunato Battaglia; Edoardo Spina; Antonio Bruno Journal: Front Psychiatry Date: 2019-10-25 Impact factor: 4.157
Authors: Igne Sinkeviciute; Marieke Begemann; Merel Prikken; Bob Oranje; Erik Johnsen; Wan U Lei; Kenneth Hugdahl; Rune A Kroken; Carina Rau; Jolien D Jacobs; Silvia Mattaroccia; Iris E Sommer Journal: NPJ Schizophr Date: 2018-10-25